Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension (S16.008)
2023 | conference paper. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension (S16.008)
Montalban, X.; Wolinsky, J. S.; Arnold, D. L.; Weber, M. S.; Piasecka-Stryczynska, K.; Tomic, D. & Seitzinger, A. et al. (2023)
p. 3752. 2023 Annual Meeting Abstracts
Lippincott Williams & Wilkins. DOI: https://doi.org/10.1212/WNL.0000000000203500
Documents & Media
Details
- Authors
- Montalban, Xavier; Wolinsky, Jerry S.; Arnold, Douglas L.; Weber, Martin S.; Piasecka-Stryczynska, Karolina; Tomic, Davorka; Seitzinger, Andrea; Guehring, Hans
- Issue Date
- 2023
- Publisher
- Lippincott Williams & Wilkins
- Conference
- 2023 Annual Meeting Abstracts
